See more : Electric Royalties Ltd. (ELEC.V) Income Statement Analysis – Financial Results
Complete financial analysis of Fresh Tracks Therapeutics, Inc. (FRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fresh Tracks Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Cigna Corporation (CGN.DE) Income Statement Analysis – Financial Results
- Nagase Brothers Inc. (9733.T) Income Statement Analysis – Financial Results
- Templeton Emerging Markets Investment Trust plc (TEM.L) Income Statement Analysis – Financial Results
- VEDANT ASSET LIMITED (VEDANTASSET.BO) Income Statement Analysis – Financial Results
- Acer Gaming Inc. (6908.TWO) Income Statement Analysis – Financial Results
Fresh Tracks Therapeutics, Inc. (FRTX)
About Fresh Tracks Therapeutics, Inc.
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.01M | 6.94M | 404.00K | 1.82M | 7.92M | 1.62M | 13.82M | 14.53M | 20.95M | 15.22M | 7.72M | 17.52M | 30.02M | 8.71M | 12.69M | 7.96M | 5.51M | 14.74M | 12.00M | 14.55M | 8.08M | 7.01M | 11.37M | 7.62M | 10.70M | 5.90M | 7.80M | 6.70M | 6.30M | 5.50M | 6.00M | 3.60M | 2.40M | 1.80M |
| Cost of Revenue | 0.00 | 14.04M | 28.23M | 11.22M | 20.21M | 1.44M | 6.48M | 6.29M | 10.93M | 10.82M | 12.70M | 0.00 | 10.27M | 11.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.20M | -1.00M | -900.00K | -900.00K | -600.00K | -500.00K | -500.00K | 5.70M | 4.00M | 3.00M | 2.20M |
| Gross Profit | 8.01M | -7.10M | -27.83M | -9.39M | -12.30M | 186.00K | 7.34M | 8.24M | 10.02M | 4.39M | -4.98M | 17.52M | 19.75M | -2.73M | 12.69M | 7.96M | 5.51M | 14.74M | 12.00M | 14.55M | 8.08M | 7.01M | 11.37M | 8.82M | 11.70M | 6.80M | 8.70M | 7.30M | 6.80M | 6.00M | 300.00K | -400.00K | -600.00K | -400.00K |
| Gross Profit Ratio | 100.00% | -102.26% | -6,887.87% | -515.59% | -155.32% | 11.47% | 53.12% | 56.71% | 47.84% | 28.87% | -64.52% | 100.00% | 65.80% | -31.28% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 115.75% | 109.35% | 115.25% | 111.54% | 108.96% | 107.94% | 109.09% | 5.00% | -11.11% | -25.00% | -22.22% |
| Research & Development | 3.18M | 14.04M | 28.23M | 11.22M | 20.21M | 12.33M | 14.39M | 10.36M | 11.06M | 11.47M | 14.56M | 17.34M | 17.98M | 19.69M | 23.45M | 25.53M | 22.93M | 18.51M | 17.77M | 31.18M | 26.78M | 26.37M | 22.07M | 18.51M | 15.30M | 12.10M | 11.90M | 11.30M | 9.00M | 8.30M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.18M | 14.43M | 12.42M | 11.58M | 12.17M | 8.94M | 12.81M | 13.35M | 19.29M | 20.38M | 24.51M | 23.61M | 0.00 | 8.80M | 7.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.44M | 6.48M | 6.29M | 10.93M | 10.82M | 12.70M | 13.06M | 0.00 | 0.00 | 10.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.18M | 14.43M | 12.42M | 11.58M | 12.17M | 8.94M | 12.81M | 13.35M | 19.29M | 20.38M | 24.51M | 23.61M | 9.60M | 8.80M | 17.82M | 19.77M | 22.84M | 22.64M | 19.88M | 8.51M | 6.92M | 8.06M | 6.52M | 5.27M | 4.40M | 3.60M | 3.70M | 3.20M | 2.90M | 2.60M | 2.00M | 1.40M | 1.10M | 800.00K |
| Other Expenses | 0.00 | 441.00K | 839.00K | 0.00 | 0.00 | -1.44M | -6.48M | -6.29M | -10.93M | -10.82M | -12.70M | -13.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 482.22K | 4.20M | 0.00 | 1.20M | 1.00M | 900.00K | 900.00K | 600.00K | 500.00K | 500.00K | 400.00K | 400.00K | 600.00K | 600.00K |
| Operating Expenses | 14.37M | 28.48M | 40.65M | 22.80M | 32.39M | 21.27M | 27.21M | 23.71M | 30.35M | 31.84M | 39.07M | 40.95M | 27.57M | 28.49M | 41.27M | 45.30M | 45.77M | 41.16M | 37.65M | 39.69M | 34.18M | 38.64M | 28.60M | 24.98M | 20.70M | 16.60M | 16.50M | 15.10M | 12.40M | 11.40M | 2.40M | 1.80M | 1.70M | 1.40M |
| Cost & Expenses | 14.37M | 28.48M | 40.65M | 22.80M | 32.39M | 21.27M | 27.21M | 23.71M | 30.35M | 31.84M | 39.07M | 40.95M | 37.84M | 39.93M | 41.27M | 45.30M | 45.77M | 41.16M | 37.65M | 39.69M | 34.18M | 38.64M | 28.60M | 23.78M | 19.70M | 15.70M | 15.60M | 14.50M | 11.90M | 10.90M | 8.10M | 5.80M | 4.70M | 3.60M |
| Interest Income | 0.00 | 9.00K | 69.00K | 63.00K | 1.94M | 61.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.83M | 2.21M | 2.07M | 3.98M | 8.29M | 9.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.00K | 9.00K | 69.00K | 0.00 | 2.10M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 21.00K | 96.00K | 272.00K | 533.00K | 795.00K | 412.82K | 288.25K | 296.58K | 204.60K | 0.00 | 200.00K | 0.00 | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 100.00K | 100.00K |
| Depreciation & Amortization | 41.00K | 30.00K | 22.00K | 10.00K | 28.00K | 49.00K | 793.00K | 1.12M | 1.16M | 1.66M | 2.21M | 1.98M | 2.30M | 2.81M | 2.63M | 2.87M | 3.26M | 3.28M | 3.59M | 3.64M | 3.54M | 2.74M | 1.88M | 1.20M | 1.00M | 900.00K | 900.00K | 600.00K | 500.00K | 500.00K | 400.00K | 400.00K | 600.00K | 600.00K |
| EBITDA | -5.65M | -21.06M | -39.38M | -20.90M | -24.47M | -19.50M | -12.59M | -8.06M | -8.25M | -14.96M | -29.14M | -21.11M | -5.32M | -28.41M | -25.93M | -34.48M | -37.00M | -23.13M | -22.06M | -21.51M | -22.56M | -28.89M | -15.35M | -14.96M | -8.00M | -8.90M | -6.90M | -7.20M | -5.10M | -4.90M | -1.70M | -1.80M | -1.70M | -1.20M |
| EBITDA Ratio | -70.55% | -303.80% | -9,961.39% | -1,151.26% | -309.06% | -1,420.35% | -99.95% | -64.56% | -40.15% | -110.14% | -407.70% | -136.81% | -27.85% | -326.10% | -204.85% | -439.20% | -752.21% | -180.97% | -183.76% | -147.86% | -273.30% | -352.37% | -135.02% | -196.31% | -74.77% | -191.53% | -119.23% | -149.25% | -107.94% | -110.91% | -43.33% | -58.33% | -75.00% | -77.78% |
| Operating Income | -6.36M | -21.53M | -40.24M | -20.98M | -24.47M | -19.65M | -13.39M | -9.18M | -9.40M | -16.63M | -31.35M | -23.43M | -7.82M | -31.22M | -28.59M | -37.34M | -40.26M | -26.42M | -25.65M | -25.14M | -26.10M | -31.63M | -17.23M | -16.16M | -9.00M | -9.80M | -7.80M | -7.80M | -5.60M | -5.40M | -2.10M | -2.20M | -2.30M | -1.80M |
| Operating Income Ratio | -79.44% | -310.15% | -9,961.39% | -1,151.26% | -309.06% | -1,211.22% | -96.87% | -63.15% | -44.89% | -109.26% | -406.22% | -133.76% | -26.06% | -358.34% | -225.34% | -469.37% | -730.44% | -179.22% | -213.70% | -172.86% | -323.12% | -451.36% | -151.59% | -212.06% | -84.11% | -166.10% | -100.00% | -116.42% | -88.89% | -98.18% | -35.00% | -61.11% | -95.83% | -100.00% |
| Total Other Income/Expenses | 666.00K | 432.00K | 770.00K | 63.00K | 591.00K | 3.39M | 426.00K | 204.00K | 166.00K | 134.00K | 114.00K | 534.00K | 539.00K | 830.00K | 28.00K | 468.00K | 4.46M | 3.54M | 0.00 | 0.00 | -481.56K | -4.20M | 0.00 | 0.00 | 0.00 | 2.40M | 2.40M | 2.80M | 1.70M | 1.20M | 900.00K | 300.00K | 100.00K | 200.00K |
| Income Before Tax | -5.69M | -21.10M | -39.47M | -20.91M | -23.88M | -16.25M | -12.96M | -8.97M | -9.24M | -16.49M | -31.24M | -22.90M | -7.28M | -30.39M | -28.56M | -36.88M | -35.80M | -22.88M | 0.00 | 0.00 | -26.59M | -35.83M | 0.00 | 0.00 | 0.00 | -7.40M | -5.40M | -5.00M | -3.90M | -4.20M | -1.20M | -1.90M | -2.20M | -1.60M |
| Income Before Tax Ratio | -71.12% | -303.93% | -9,770.79% | -1,147.80% | -301.59% | -1,002.10% | -93.78% | -61.75% | -44.10% | -108.38% | -404.74% | -130.71% | -24.26% | -348.81% | -225.10% | -463.49% | -649.46% | -155.20% | 0.00% | 0.00% | -329.09% | -511.30% | 0.00% | 0.00% | 0.00% | -125.42% | -69.23% | -74.63% | -61.90% | -76.36% | -20.00% | -52.78% | -91.67% | -88.89% |
| Income Tax Expense | 0.00 | -441.00K | 47.00K | -10.00K | 2.07M | 4.48M | -1.22M | -1.32M | -166.00K | -1.80M | -2.33M | -2.52M | -2.84M | 0.00 | -28.00K | -447.00K | -4.37M | -3.27M | -1.29M | -1.41M | -1.65M | -3.70M | -7.99M | -7.64M | -2.10M | -2.30M | -2.20M | -2.70M | -1.60M | -1.00M | -700.00K | -200.00K | 0.00 | -100.00K |
| Net Income | -5.69M | -20.66M | -39.52M | -20.90M | -25.95M | -16.25M | -12.96M | -8.97M | -9.24M | -16.49M | -31.24M | -22.90M | -7.28M | -30.39M | -28.56M | -36.90M | -35.89M | -23.15M | -24.36M | -23.73M | -24.45M | -27.93M | -9.24M | -8.52M | -6.90M | -7.50M | -5.60M | -5.10M | -4.00M | -4.40M | -1.40M | -2.00M | -2.30M | -1.70M |
| Net Income Ratio | -71.12% | -297.58% | -9,782.43% | -1,147.26% | -327.71% | -1,002.10% | -93.78% | -61.75% | -44.10% | -108.38% | -404.74% | -130.71% | -24.26% | -348.81% | -225.11% | -463.75% | -651.20% | -157.04% | -202.92% | -163.17% | -302.65% | -398.62% | -81.29% | -111.77% | -64.49% | -127.12% | -71.79% | -76.12% | -63.49% | -80.00% | -23.33% | -55.56% | -95.83% | -94.44% |
| EPS | -0.96 | -7.36 | -22.14 | -38.37 | -386.21 | -234.41 | -316.76 | -282.12 | -317.17 | -585.11 | -1.13K | -839.10 | -318.51 | -1.59K | -1.91K | -2.92K | -2.89K | -2.32K | -3.12K | -3.29K | -3.83K | -4.38K | -1.45K | -1.36K | -1.35K | -1.50K | -1.14K | -1.04K | -913.45 | -1.07K | -440.94 | -724.38 | -850.59 | -693.03 |
| EPS Diluted | -0.96 | -7.36 | -22.14 | -38.37 | -386.21 | -234.41 | -316.76 | -282.12 | -317.17 | -585.11 | -1.13K | -839.10 | -318.51 | -1.59K | -1.91K | -2.92K | -2.89K | -2.32K | -3.12K | -3.29K | -3.83K | -4.38K | -1.45K | -1.36K | -1.35K | -1.49K | -1.14K | -1.04K | -913.45 | -1.07K | -440.94 | -724.38 | -850.59 | -693.03 |
| Weighted Avg Shares Out | 5.91M | 2.81M | 1.78M | 544.76K | 67.18K | 69.34K | 40.91K | 31.81K | 29.13K | 28.19K | 27.57K | 27.29K | 22.87K | 19.07K | 14.95K | 12.65K | 12.44K | 9.98K | 7.80K | 7.20K | 6.38K | 6.37K | 6.36K | 6.25K | 5.12K | 5.02K | 4.92K | 4.88K | 4.38K | 4.11K | 3.18K | 2.76K | 2.70K | 2.45K |
| Weighted Avg Shares Out (Dil) | 5.91M | 2.81M | 1.78M | 544.76K | 67.18K | 69.34K | 40.91K | 31.81K | 29.13K | 28.19K | 27.57K | 27.29K | 22.87K | 19.07K | 14.95K | 12.65K | 12.44K | 9.98K | 7.80K | 7.20K | 6.38K | 6.37K | 6.36K | 6.25K | 5.12K | 5.04K | 4.93K | 4.89K | 4.38K | 4.11K | 3.18K | 2.76K | 2.70K | 2.45K |
4 Reddit Penny Stocks To Buy On Robinhood For Under $1 Right Now
Penny stocks on Robinhood are a big focus for Reddit traders in April The post 4 Reddit Penny Stocks To Buy On Robinhood For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information |...
Biotech Penny Stocks To Buy? 3 to Watch Under $5
Biotech stocks are more popular than ever; here are 3 to watch under $5 The post Biotech Penny Stocks To Buy? 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis
Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment
Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology's 2021 VMX
BOULDER, Colo., April 16, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that results...
BBI Stock Price Increases Over 8% Pre-Market: Why It Happened
The stock price of Brickell Biotech Inc (NASDAQ: BBI) has increased by over 8% pre-market. This is why it happened.
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q4 2020 Results - Earnings Call Transcript
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q4 2020 Results - Earnings Call Transcript
Brickell (BBI) Reports Q4 Loss, Misses Revenue Estimates
Brickell (BBI) delivered earnings and revenue surprises of -87.50% and -97.30%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Brickell Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Initiated U.S. pivotal Phase 3 clinical program (Cardigan I and II studies) evaluating sofpironium bromide gel, 15% for the treatment of primary axillary (underarm) hyperhidrosis
Brickell Biotech To Host Key Opinion Leader Webinar on the Hyperhidrosis Market
Webinar taking place on Friday, March 26th @ 10 am EDT Webinar taking place on Friday, March 26th @ 10 am EDT
Will Brickell (BBI) Report Negative Earnings Next Week? What You Should Know
Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Source: https://incomestatements.info
Category: Stock Reports